2 results
Approved WMORecruiting
To determine if the addition of midostaurin to daunorubicin/ cytarabine induction, high dose cytarabine consolidation, and continuation therapy improves overall survival (OS) in both the mutant FLT3-ITD and FLT-3 TKD AML patients.
Approved WMOCompleted
PRIMARY OBJECTIVETo evaluate the safety and tolerability of single ascending, intravenous doses of ACT017 administered as a 6-hour intravenous (i.v.) infusionSECONDARY OBJECTIVES* To evaluate the pharmacokinetics of single ascending, intravenous…